Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome (Q79172610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

5

Ginger J Gardner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Amer K Karam

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Antonio Santillan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Robert E Bristow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Robert Giuntoli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ilana Cass

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Beth Y Karlan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Andrew J Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

2 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

377-380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Secondary cytoreduction for ovarian cancer following cisplatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

Tertiary cytoreduction in patients with recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.037

10.1016/J.YGYNO.2006.08.037

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17014899%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference